GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (TSE:4503) » Definitions » Net Cash per Share

Astellas Pharma (TSE:4503) Net Cash per Share : 円-881.20 (As of Dec. 2023)


View and export this data going back to 1949. Start your Free Trial

What is Astellas Pharma Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Astellas Pharma's Net Cash per Share for the quarter that ended in Dec. 2023 was 円-881.20.

The historical rank and industry rank for Astellas Pharma's Net Cash per Share or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Cash Ratio of Astellas Pharma was 147.89. The lowest was 64.80. And the median was 83.10.

TSE:4503's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.47
* Ranked among companies with meaningful Price-to-Net-Cash only.

Astellas Pharma Net Cash per Share Historical Data

The historical data trend for Astellas Pharma's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Net Cash per Share Chart

Astellas Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -172.64 -375.85 -299.95 -292.71 -307.19

Astellas Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -290.21 -307.19 -343.24 -857.11 -881.20

Competitive Comparison of Astellas Pharma's Net Cash per Share

For the Drug Manufacturers - General subindustry, Astellas Pharma's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Price-to-Net-Cash falls into.



Astellas Pharma Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Astellas Pharma's Net Cash per Share for the fiscal year that ended in Mar. 2023 is calculated as

Net Cash per Share (A: Mar. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(396624-948564-0)/1796.76
=-307.19

Astellas Pharma's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(285436-1865427-0)/1792.99
=-881.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Astellas Pharma  (TSE:4503) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Astellas Pharma Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma (TSE:4503) Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.

Astellas Pharma (TSE:4503) Headlines

No Headlines